{"id":"vunakizumab-and-recaticimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (upper respiratory, urinary tract)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vunakizumab is an anti-IL-12/IL-23 monoclonal antibody that blocks the p40 subunit shared by both IL-12 and IL-23, reducing Th1 and Th17 cell differentiation. Recaticimab is an anti-TNF-α monoclonal antibody that inhibits tumor necrosis factor-alpha signaling. Together or individually, these agents suppress pro-inflammatory pathways implicated in autoimmune and inflammatory diseases.","oneSentence":"Vunakizumab and recaticimab are monoclonal antibodies that target inflammatory cytokines to modulate immune responses in inflammatory and autoimmune conditions.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:16:03.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory bowel disease"},{"name":"Psoriasis"},{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT07373847","phase":"PHASE4","title":"Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia","status":"NOT_YET_RECRUITING","sponsor":"Xiangya Hospital of Central South University","startDate":"2026-01-20","conditions":"Plaque Psoriasis","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"vunakizumab and recaticimab.","genericName":"vunakizumab and recaticimab.","companyName":"Xiangya Hospital of Central South University","companyId":"xiangya-hospital-of-central-south-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vunakizumab and recaticimab are monoclonal antibodies that target inflammatory cytokines to modulate immune responses in inflammatory and autoimmune conditions. Used for Inflammatory bowel disease, Psoriasis, Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}